FDA Approves NAPROXEN SODIUM — ScieGen Pharmaceuticals, Inc.

ScieGen Pharmaceuticals, Inc. has received FDA approval for its Abbreviated New Drug Application for Naproxen Sodium, launching an additional generic entry into the pain relief market. This approval will likely intensify price competition and compress margins for branded and competing generic manufacturers, though incremental sales are expected from patients seeking substitution to the ScieGen product.